Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | TRPV3 | Q8NET8 | 3/20 | 0.41 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.33 |
| ▸ | AKT1S1 | Q96B36 | 1/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699032 | 0.83 | MAP4K4 (0.41) | MAP4K4TRPV3EIF2AK4PDE10AMBOAT4 | |
| SCHEMBL19699033 | 0.80 | MAP4K4 (0.42) | MAP4K4TRPV3EIF2AK4 | |
| SCHEMBL20733270 | 0.80 | PDE10A (0.33) | PDE10A | |
| SCHEMBL19670180 | 0.76 | HRH3 (0.34) | — | |
| SCHEMBL20733299 | 0.74 | EGLN2 (0.39) | — | |
| SCHEMBL16754630 | 0.71 | MAP4K4 (0.47) | MAP4K4TRPV3EIF2AK4PDE10AMBOAT4 | |
| SCHEMBL17778528 | 0.71 | MAP4K4 (0.46) | MAP4K4TRPV3EIF2AK4PDE10A | |
| SCHEMBL16754566 | 0.71 | MAP4K4 (0.46) | MAP4K4TRPV3EIF2AK4PDE10A | |
| SCHEMBL19706295 | 0.70 | FGFR4 (0.40) | MAP4K4TRPV3PDE10AMAP3K12 | |
| SCHEMBL16775802 | 0.70 | SMN1; SMN2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-02-14 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MAP4K4 2229/4885TRPV3 4093/4885EIF2AK4 1123/4885 |
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MAP4K4 1898/4885TRPV3 4136/4885EIF2AK4 926/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | MAP4K4 2229/4885TRPV3 4093/4885EIF2AK4 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.